Kodiak Sciences
Yahoo Finance • last year
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y... Full story
Yahoo Finance • last year
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PALO ALTO, Calif., Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases... Full story
Yahoo Finance • 2 years ago
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
PALO ALTO, Calif., Aug. 5, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases,... Full story
Yahoo Finance • 3 years ago
Stock rebound uncertain for U.S. biotechs as risks multiply for investors
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.... Full story
